Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
Capecitabine [aka Xeloda] has been approved for use
in North America [USA & Canada] in recurrent or metastatic breast cancer since 2000 at the latest.
Adriamycin-based combinations followed by a taxane
are the standard of care; capecitabine should be an obvious
Another point is that Xeloda is a chemically trivial
modification of 5-fluorouracil, formulated to enhance
tumor targeting and binding.
Is this recommendation really a mark of clinical excellence,
or a long-deferred catch-up in best practice?
No competing interests
30 May 2003
Brian M. Lynch
Senior Research Professor
St. Francis Xavier University, Antigonish B2G 2W5, Nova Scotia, Canada